Trading Update
The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").
8 October 2026
MYCELX Technologies Corporation
("MYCELX" or the "Company")
Trading Update
MYCELX Technologies Corporation (AIM: MYX), a leading provider of proprietary water treatment technology to the Oil and Gas and other industries worldwide, provides an update on trading.
As announced most recently in the AGM statement on 17 September 2026, revenue expectations for the current financial year depended on timing of the expected award of a significant project for an overseas customer in the Middle East. The associated revenue recognition in FY2026 required receipt of the customer’s purchase order in time to deliver the equipment before year end.
As the purchase order has not been received within the required fabrication window, the Board now expects that the c.a. $2 million of revenue associated with this project will be delivered in FY2027. On this basis, this revenue is expected to increase the total revenue for FY2027 by the same amount. The Board believes the underlying opportunity remains strong, with the customer indicating that it is committed to executing this project as well as its current and future expansion plans.
Separately, one of the Company’s major customers for MYCELX’s media product has experienced disruption at a high-production offshore site. Initially this site was expected to resume operations within a relatively short shutdown period. However, the Company recently learned that resolving all issues will take longer than expected. This will impact the level of media sales, and therefore FY2026 revenue, by a further estimated $1 million to $1.5 million.
Notwithstanding these headwinds, which are expected to impact the current year principally, the Board remains confident in the opportunity available to MYCELX in 2027 and beyond with multiple contracts expected to be awarded for delivery next year. As the Company continues to execute its scale-up strategy and expand its revenue base, the Board expects the impact of individual project delays and production disruptions, which are common in the Company’s core markets, to become less significant to the overall business. The current pipeline includes 11 potential project awards with two US super majors and one Middle Eastern National producer expected to be awarded in the next 6-12 months and potentially worth a total of $20 million - $22 million. The timing of contract awards will dictate delivery and revenue recognition.
To ensure that momentum is not affected and to provide working capital flexibility, the Company has agreed to enter into a short-term bridge loan of up to $500K from its CEO, Connie Mixon. Under the terms of the agreement, the loan may be drawn down in whole or part at any time during its term of 9 months and it has an interest rate of 10%. The loan is unsecured.
As a Director of the Company, Connie Mixon is a related party under the definition of the AIM Rules for Companies and accordingly the entering into of the loan agreement is deemed to be a related party transaction pursuant to AIM Rule 13 of the AIM Rule for Companies.
The Company's Directors (excluding Connie Mixon), having consulted with the Company's Nominated Adviser, Cavendish Capital Markets Limited, consider the terms of the loan, as described above, are fair and reasonable insofar as the shareholders are concerned.
Connie Mixon, CEO, commented:
"Our underlying opportunities are stronger with more visibility than any other time in Company history. While the delay in timing of the overseas project and unexpected disruption to media volumes will affect near-term revenue, we remain focused on securing significant contracts in the US and overseas. We are confident in our customer relationships, technology, and projects supporting our 2027 outlook.
The Company believes that the scale-up strategy will mitigate delays and disruptions and their impact on its overall business. With funded opportunities advancing and capital projects positioned to expand our recurring revenue base, we believe MYCELX is well placed for a strong 2027 and continued progress against our scale-up strategy”.
For further information, please contact:
|
MYCELX Technologies Corporation Connie Mixon, CEO Kim Slayton, CFO
|
Tel: +1 888 306 6843 |
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) Giles Balleny / Callum Davidson / Elysia Bough (Corporate Finance) Harriet Ward (Corporate Broking) Jasper Berry / Michael Johnson (Sales) |
Tel: +44 20 7220 0500
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE